January 24th 2025
The collaboration will combine fully automated and digitalized technologies to reduce CGT manufacturing timelines to 2.5 days.
Avid and Argonaut Enter into Manufacturing Solutions Co-Marketing Agreement
July 29th 2020The companies will utilize Avid’s upstream and downstream process development and drug substance manufacturing services in conjunction with Argonaut’s parenteral drug product fill-finish services for the delivery of CGMP parenteral drug products for use in clinical studies.
Roche, Blueprint Medicines Enter $1.7-Billion Deal for Anti-Cancer Drug
July 15th 2020Through the deal, Roche will gain co-commercialization rights to pralsetinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of RET-altered non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancer
SGS Initiates Clinical Trial of Biophytis’ Treatment for COVID-19 Related Respiratory Failure
July 8th 2020SGS has announced the receipt of approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to begin a new clinical trial of a potential treatment for patients with COVID-19 related respiratory failure.
Emergent and Johnson & Johnson Enter into $480 Million Manufacturing Agreement for COVID-19 Vaccine
July 6th 2020Emergent is entering into a five-year agreement with Janssen Pharmaceuticals for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.
CHMP Recommends Marketing Authorization for Triple Combination Therapy for Cystic Fibrosis
July 1st 2020EMA’s Committee for Human Medicinal Products (CHMP) has recommended that Kaftrio, a triple combination therapy for the treatment of cystic fibrosis, be authorized for marketing in the European Union.
Genomics England Launches Next-Generation Genomics Research Platform
July 1st 2020Genomics England (GEL) has announced the launch of a next-generation genomics research platform, supported by Lifebit-a deep tech company-and Amazon Web Services (AWS), which will be primarily dedicated for COVID-19 research.